Altimmune reported earnings of -$ 0.15 per ALT share on Nov 12, 2026, beating analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 0.13 |
| Earnings Per Share (Surprise) | -$ 0.15 (-$ 0.02) |
| Last Year's EPS | -$ 0.25 |
| EPS YoY Change |
Out of the last 85 earnings reporting periods, Altimmune beat analysts’ expectations 43 times and fell short of expectations 18 time(s). Altimmune reported earnings per share of -$ 0.15 in the last report falling to reach an estimated EPS of -$ 0.13 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.13 | -$ 0.15 | -$ 0.21 | |
| Aug 11, 2026 | -$ 0.14 | -$ 0.12 | -$ 0.27 | |
| May 13, 2026 | -$ 0.25 | -$ 0.18 | -$ 0.26 | |
| Mar 5, 2026 | -$ 0.25 | -$ 0.27 | -$ 0.33 | |
| Nov 6, 2025 | -$ 0.29 | -$ 0.21 | -$ 0.32 | |
| Aug 12, 2025 | -$ 0.32 | -$ 0.27 | -$ 0.35 | |
| May 13, 2025 | -$ 0.35 | -$ 0.26 | -$ 0.34 | |
| Feb 27, 2025 | -$ 0.34 | -$ 0.33 | -$ 0.33 | |
| Nov 12, 2024 | -$ 0.36 | -$ 0.32 | -$ 0.39 | |
| Aug 8, 2024 | -$ 0.34 | -$ 0.35 | -$ 0.32 | |
| May 9, 2024 | -$ 0.36 | -$ 0.34 | -$ 0.40 | |
| Mar 27, 2024 | -$ 0.43 | -$ 0.33 | -$ 0.43 | |
| Nov 7, 2023 | -$ 0.40 | -$ 0.39 | -$ 0.48 | |
| Aug 10, 2023 | -$ 0.44 | -$ 0.32 | -$ 0.42 | |
| May 11, 2023 | -$ 0.49 | -$ 0.40 | -$ 0.44 | |
| Feb 28, 2023 | -$ 0.52 | -$ 0.43 | -$ 0.49 | |
| Nov 10, 2022 | -$ 0.49 | -$ 0.48 | -$ 0.81 | |
| Aug 11, 2022 | -$ 0.45 | -$ 0.42 | -$ 0.40 | |
| May 12, 2022 | -$ 0.57 | -$ 0.44 | -$ 0.38 | |
| Mar 15, 2022 | -$ 0.64 | -$ 0.49 | -$ 0.17 |
Altimmune’s stock was trading at $ 1.93 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, ALT’s price decreased to $ 1.65 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.15 | $ 1.93 | $ 1.65 | |
| Aug 11, 2026 | -$ 0.12 | $ 3.05 | $ 2.93 | |
| May 13, 2026 | -$ 0.18 | $ 3.08 | $ 2.92 | |
| Mar 5, 2026 | -$ 0.27 | $ 4.27 | $ 3.54 | |
| Nov 6, 2025 | -$ 0.21 | $ 3.75 | $ 4.11 | |
| Aug 12, 2025 | -$ 0.27 | $ 3.38 | $ 3.74 | |
| May 13, 2025 | -$ 0.26 | $ 6.01 | $ 5.70 | |
| Feb 27, 2025 | -$ 0.33 | $ 5.94 | $ 6.65 | |
| Nov 12, 2024 | -$ 0.32 | $ 7.35 | $ 9.52 | |
| Aug 8, 2024 | -$ 0.35 | $ 5.50 | $ 6.17 | |
| May 9, 2024 | -$ 0.34 | $ 7.16 | $ 7.22 | |
| Mar 27, 2024 | -$ 0.33 | $ 8.65 | $ 10.18 | |
| Nov 7, 2023 | -$ 0.39 | $ 2.67 | $ 2.70 | |
| Aug 10, 2023 | -$ 0.32 | $ 2.95 | $ 3.01 | |
| May 11, 2023 | -$ 0.40 | $ 4.98 | $ 5.09 | |
| Feb 28, 2023 | -$ 0.43 | $ 11.83 | $ 12.05 | |
| Nov 10, 2022 | -$ 0.48 | $ 9.69 | $ 10.69 | |
| Aug 11, 2022 | -$ 0.42 | $ 12.86 | $ 17.36 | |
| May 12, 2022 | -$ 0.44 | $ 3.94 | $ 5.16 | |
| Mar 15, 2022 | -$ 0.49 | $ 6.43 | $ 6.57 |
Altimmune released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Altimmune missed analysts’ expectations during the last earnings period by
